DK1375512T3 - Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger - Google Patents

Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger

Info

Publication number: DK1375512T3
Authority: DK; Denmark
Prior art keywords: approved; immunogenic compositions; measles virus; vaccine strain; virus vaccine
Prior art date: 2002-06-20

Application number

DK02291551T

Other languages

English (en)

Inventor

Frederic Tangy

Chantal Combredet

Valerie Labrousse-Najburg

Michel Brahic

Original Assignee

Pasteur Institut

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-20

Filing date

2002-06-20

Publication date

2009-10-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1375512(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-20 Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut

2009-10-26 Application granted granted Critical

2009-10-26 Publication of DK1375512T3 publication Critical patent/DK1375512T3/da

Links

239000002299 complementary DNA Substances 0.000 title abstract 3
230000002163 immunogen Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
229940124862 Measles virus vaccine Drugs 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
230000002458 infectious effect Effects 0.000 title 1
241000712079 Measles morbillivirus Species 0.000 abstract 2
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/12—Mumps virus; Measles virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10241—Use of virus, viral particle or viral elements as a vector
- C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

DK02291551T 2002-06-20 2002-06-20 Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger DK1375512T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02291551A EP1375512B1 (en)	2002-06-20	2002-06-20	Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions

Publications (1)

Publication Number	Publication Date
DK1375512T3 true DK1375512T3 (da)	2009-10-26

Family

ID=29716946

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02291551T DK1375512T3 (da)	2002-06-20	2002-06-20	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
DK10184511.3T DK2311853T3 (da)	2002-06-20	2003-06-20	Infektiøst cDNA af en godkendt vaccinestamme for mæslingevirus. Anvendelse for immunogene sammensætninger

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10184511.3T DK2311853T3 (da)	2002-06-20	2003-06-20	Infektiøst cDNA af en godkendt vaccinestamme for mæslingevirus. Anvendelse for immunogene sammensætninger

Country Status (14)

Country	Link
US (3)	US9005961B2 (da)
EP (5)	EP1375512B1 (da)
KR (1)	KR101227128B1 (da)
CN (1)	CN100577683C (da)
AT (1)	ATE437175T1 (da)
AU (1)	AU2003266950A1 (da)
BR (1)	BRPI0312173B8 (da)
CA (1)	CA2489052C (da)
CY (1)	CY1109506T1 (da)
DE (1)	DE60233038D1 (da)
DK (2)	DK1375512T3 (da)
ES (2)	ES2330309T3 (da)
PT (1)	PT1375512E (da)
WO (1)	WO2004000876A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1201750A1 (en)	2000-10-26	2002-05-02	Genopoietic	Synthetic viruses and uses thereof
EP1375670B1 (en) *	2002-06-20	2013-06-12	Institut Pasteur	Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
DK1375512T3 (da) *	2002-06-20	2009-10-26	Pasteur Institut	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
CA2432738A1 (en)	2003-02-26	2004-08-26	Philippe Despres	New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2009005917A2 (en) *	2007-05-29	2009-01-08	Vical Incorporated	Methods of treating measles infectious disease in mammals
JP5619614B2 (ja) *	2007-11-26	2014-11-05	ロンドンスクールオブハイジーンアンドトロピカルメディシンＬｏｎｄｏｎＳｃｈｏｏｌＯｆＨｙｇｉｅｎｅ＆ＴｒｏｐｉｃａｌＭｅｄｉｃｉｎｅ	レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法
EP2085479A1 (en) *	2008-01-31	2009-08-05	Institut Pasteur	Reverse genetics of negative-strand rna viruses in yeast
EP2420242A1 (en)	2010-08-20	2012-02-22	Lauer, Ulrich M.	Oncolytic measles virus
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
EP2712871A1 (en)	2012-09-27	2014-04-02	Institut Pasteur	Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en)	2013-01-24	2014-07-30	Institut Pasteur	Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
EP2959915A1 (en)	2014-06-23	2015-12-30	Institut Pasteur	A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3103474A1 (en) *	2015-06-12	2016-12-14	Institut Pasteur	Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
EP3184119A1 (en)	2015-12-23	2017-06-28	Themis Bioscience GmbH	Chromatography based purification strategies for measles scaffold based viruses
JP6949468B2 (ja) *	2016-10-17	2021-10-13	ルプレヒト−カールス−ウニベルジテートハイデルベルク	腫瘍抗原をコードする麻疹ウイルス
US11351246B2 (en)	2017-05-09	2022-06-07	Invectys SAS	Recombinant measles vaccine expressing hTERT
EP3412307A1 (en)	2017-06-07	2018-12-12	Institut Pasteur	Recombinant measles virus expressing zika virus proteins and their applications
SG11202004234SA (en)	2017-11-09	2020-06-29	Pasteur Institut	A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
AU2018392826B2 (en) *	2017-12-21	2025-10-09	Centre National De La Recherche Scientifique	Lassa vaccine
CN111218475A (zh) *	2018-11-23	2020-06-02	成都生物制品研究所有限责任公司	一种拯救麻疹Schwarz/Moraten疫苗株的系统和方法
EP3865180A1 (en) *	2020-02-13	2021-08-18	Institut Pasteur	Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
CA3166811A1 (en) *	2020-02-13	2021-08-19	Nicolas Robert Xavier Escriou	Measles-vectored covid-19 immunogenic compositions and vaccines
EP3936517A1 (en)	2020-07-08	2022-01-12	Institut Pasteur	An improved measles virus vaccine vector based on multiple tandem additional transcription units
CA3204201A1 (en)	2021-01-13	2022-07-21	Thierry Heidmann	Measles-hiv or measles-htlv vaccine
CN113293148B (zh) *	2021-03-10	2022-10-25	上海青赛生物科技有限公司	一种h基因替换的嵌合麻疹减毒株的构建
WO2022195900A1 (ja) *	2021-03-15	2022-09-22	国立大学法人東京大学	組換え麻疹ウイルス
WO2026013289A1 (en)	2024-07-12	2026-01-15	Institut Pasteur	Measles-mumps-rubella (mmr) vaccines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7007491A (en)	1990-02-02	1991-08-08	Schweiz. Serum- & Impfinstitut Bern	Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja)	1991-10-14	2000-05-29	社団法人北里研究所	麻疹ワクチンウイルス株同定方法
ATE181112T1 (de) *	1995-08-09	1999-06-15	Schweiz Serum & Impfinst	Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2265554A1 (en) *	1996-09-27	1998-04-02	American Cyanamid Company	3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
EP0977587B1 (en)	1997-02-28	2005-06-15	Acambis Inc.	Chimeric flavivirus vaccines
BRPI9701774B8 (pt) *	1997-04-11	2015-09-29	Fundação Oswaldo Cruz Fiocruz	cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) *	1997-05-23	2002-06-25	United States Of America	Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
CA2323927A1 (en) *	1998-03-26	1999-09-30	American Cyanamid Company	Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
KR100619319B1 (ko) *	1998-06-03	2006-09-06	와이어쓰 홀딩스 코포레이션	리보핵산 바이러스의 신규 구제방법
US6146642A (en)	1998-09-14	2000-11-14	Mount Sinai School Of Medicine, Of The City University Of New York	Recombinant new castle disease virus RNA expression systems and vaccines
EP1218499A2 (en) *	1999-08-02	2002-07-03	Wyeth	RESCUE OF MUMPS VIRUS FROM cDNA
ES2319864T3 (es) *	2000-04-28	2009-05-14	St. Jude Children's Research Hospital	Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
DK1375512T3 (da) *	2002-06-20	2009-10-26	Pasteur Institut	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
EP1375670B1 (en)	2002-06-20	2013-06-12	Institut Pasteur	Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
CA2432738A1 (en)	2003-02-26	2004-08-26	Philippe Despres	New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr)	2005-06-20	2006-12-20	Institut Pasteur	Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es)	2006-12-22	2013-09-20	Institut Pasteur	Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
US9623098B2 (en) *	2008-05-26	2017-04-18	Cadila Healthcare Limited	Combined measles-human papilloma vaccine
US9119815B2 (en) *	2009-05-05	2015-09-01	Cadila Healthcare Limited	Combined measles-malaria vaccine

2002
- 2002-06-20 DK DK02291551T patent/DK1375512T3/da active
- 2002-06-20 DE DE60233038T patent/DE60233038D1/de not_active Expired - Lifetime
- 2002-06-20 AT AT02291551T patent/ATE437175T1/de active
- 2002-06-20 ES ES02291551T patent/ES2330309T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP02291551A patent/EP1375512B1/en not_active Expired - Lifetime
- 2002-06-20 PT PT02291551T patent/PT1375512E/pt unknown
- 2002-06-20 EP EP09165802A patent/EP2110382A1/en not_active Withdrawn
2003
- 2003-06-20 CA CA2489052A patent/CA2489052C/en not_active Expired - Lifetime
- 2003-06-20 EP EP08169719A patent/EP2065393A1/en not_active Withdrawn
- 2003-06-20 EP EP10184511.3A patent/EP2311853B1/en not_active Expired - Lifetime
- 2003-06-20 KR KR1020047020803A patent/KR101227128B1/ko not_active Expired - Lifetime
- 2003-06-20 BR BRPI0312173A patent/BRPI0312173B8/pt not_active IP Right Cessation
- 2003-06-20 CN CN03814471A patent/CN100577683C/zh not_active Expired - Lifetime
- 2003-06-20 DK DK10184511.3T patent/DK2311853T3/da active
- 2003-06-20 AU AU2003266950A patent/AU2003266950A1/en not_active Abandoned
- 2003-06-20 ES ES10184511.3T patent/ES2663224T3/es not_active Expired - Lifetime
- 2003-06-20 WO PCT/EP2003/007145 patent/WO2004000876A1/en not_active Ceased
- 2003-06-20 EP EP03747858A patent/EP1513872A1/en not_active Ceased
2004
- 2004-12-17 US US11/013,786 patent/US9005961B2/en active Active
2008
- 2008-07-24 US US12/219,570 patent/US9005925B2/en not_active Expired - Lifetime
2009
- 2009-09-18 CY CY20091100970T patent/CY1109506T1/el unknown
2015
- 2015-03-24 US US14/667,088 patent/US9701944B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT1375512E (pt)	2009-09-23
EP2311853A1 (en)	2011-04-20
US20050227224A1 (en)	2005-10-13
CN1662553A (zh)	2005-08-31
CA2489052C (en)	2014-07-29
BR0312173A (pt)	2005-04-05
KR101227128B1 (ko)	2013-01-29
KR20050058288A (ko)	2005-06-16
BRPI0312173B1 (pt)	2019-05-07
US20130296541A1 (en)	2013-11-07
CA2489052A1 (en)	2003-12-31
EP1513872A1 (en)	2005-03-16
EP2065393A1 (en)	2009-06-03
ES2663224T3 (es)	2018-04-11
DE60233038D1 (de)	2009-09-03
EP1375512B1 (en)	2009-07-22
EP2110382A1 (en)	2009-10-21
US9005925B2 (en)	2015-04-14
US9005961B2 (en)	2015-04-14
US9701944B2 (en)	2017-07-11
AU2003266950A1 (en)	2004-01-06
ATE437175T1 (de)	2009-08-15
EP2311853B1 (en)	2017-12-27
HK1061568A1 (en)	2004-09-24
ES2330309T3 (es)	2009-12-09
WO2004000876A1 (en)	2003-12-31
DK2311853T3 (da)	2018-04-16
US20150275184A1 (en)	2015-10-01
CN100577683C (zh)	2010-01-06
BRPI0312173B8 (pt)	2021-05-25
CY1109506T1 (el)	2014-08-13
AU2003266950A8 (en)	2004-01-06
WO2004000876A8 (en)	2005-03-03
EP1375512A1 (en)	2004-01-02

Publication	Publication Date	Title
DK1375512T3 (da)	2009-10-26	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
DK1487485T3 (da)	2011-03-14	Imidazoquinolinadjuvanser til DNA-vacciner
DE69532369D1 (de)	2004-02-05	Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
CY1107146T1 (el)	2012-05-23	Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
ATE527281T1 (de)	2011-10-15	Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
MA30581B1 (fr)	2009-07-01	Vaccin viral recombinant
ATE430207T1 (de)	2009-05-15	Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
EA200870237A1 (ru)	2009-06-30	Последовательности пептидов и композиции
ATE419369T1 (de)	2009-01-15	Chimäre mensch-rinder respiratory syncytial virus vakzinen
EA200600403A1 (ru)	2006-08-25	Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
DE602004018975D1 (de)	2009-02-26	Promotoren zur expression im modifizierten vacciniavirus ankara
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
EP1989316A4 (en)	2011-01-05	METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
WO2005011571A3 (en)	2006-01-05	Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2006062637A3 (en)	2006-08-17	Influenza vaccination
DK1383796T3 (da)	2009-08-17	Neurovirulent stamme af viruset West Nile og anvendelser heraf
ATE493146T1 (de)	2011-01-15	Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
DK1602360T3 (da)	2012-02-13	Fremgangsmåde til opnåelse af sneglestrukturer, vaccinesammensætninger, adjuvanser og mellemprodukter dertil
ATE414905T1 (de)	2008-12-15	Diabetesmodell
MX2019014819A (es)	2021-06-10	Plásmido para inserción simplificada de secuencias cortas de adn en un cistrón que codifica para una proteína de cápside potyviral y método de aplicación.
AR073595A1 (es)	2010-11-17	Vacunas que contienen variantes geneticas de parvovirus canino
CY1116537T1 (el)	2017-03-15	Ν-φαινυλ-διοξο-υδροπυριμιδινες χρησιμες ως αναστολεις ιου ηπατιτιδας c (hcv)
NO20042505L (no)	2004-08-06	Ekspresjons-vektorer
CY1113749T1 (el)	2016-06-22	Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους
EA200701201A1 (ru)	2007-10-26	Новая фармацевтическая композиция для вакцин